Eli Lilly and Biograil join forces in easy-to-swallow partnership

The Danish company’s encapsulated device has the potential to turn injectable medicines into pills, says Biograil CEO Karsten Lindhardt, emphasizing that the smaller the pill, the better for patients.

Karsten Lindhardt, CEO of Biograil | Photo: Biograil / PR

US-based pharmaceutical company Eli Lilly has entered a new collaboration and licensing agreement with Danish biotech company Biograil, the latter announced on Tuesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs